Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality in critically ill neonates. Nephrotoxic medication exposure is common in neonates. Nephrotoxicity represents the most potentially avoidable cause of AKI in this population.
INTRODUCTION
Acute Kidney Injury (AKI) in the intensive care setting is an important contributing factor to the morbidity and mortality of critically ill neonates [1 & ,2,3,4 & ,5]. Recent studies evaluating the epidemiology of AKI have shown that it is common in the neonatal intensive care unit (NICU) with an incidence varying between 18 and 70%, depending on the studied population [3,4 & ,5-7] . Critically ill neonatal populations known to be at increased risk of developing AKI include those with congenital heart disease, perinatal asphyxia, sepsis, premature birth, and those who receive extracorporeal membrane oxygenation (ECMO). The current approach to diagnose AKI in neonates is based upon a rise in serum creatinine (SCr) or changes in urine output. SCr has a number of challenges as a biomarker for kidney function that results from the unique neonatal physiology, including the presence of maternal creatinine, creatinine reabsorption in the proximal tubules, overall lower glomerular filtration rates (GFRs), and maturational differences. In recent years, there has been an evolution in AKI definitions from arbitrary definitions to standardized staged definitions. The neonatal modified Kidney Diseases: Improving Global Outcomes has been adopted by many researchers to define neonatal AKI (Table 1 ) [8] . This definition relies on a rise in SCr from a previous trough or a decrease in urine output, and defines three levels of AKI.
Utilizing modern definitions of AKI, a number of studies have shown that AKI occurs commonly in critically ill newborns and is associated with adverse outcomes. In 2011, Koralkar et al. [6] reported an 18% incidence of AKI in very low birth weight (VLBW) infants. The mortality in infants with AKI was significantly higher than those without AKI (42 vs. 5%, P < 0.001). After adjusting for potential confounders, those with AKI had a significantly higher chance of death [hazard ratio (HR) 2.4, 95% confidence interval (CI) 0.95-6.0; P < 0.06]. AKI is a major complication in children who undergo cardiopulmonary bypass surgery. In a recent prospective multicenter study, AKI occurred in 64% of the neonates with congenital heart disease undergoing cardiopulmonary bypass. ICU length of stay and duration of mechanical ventilation were longer in those newborns who developed AKI [9] . In a multicenter study, noncardiac neonates on ECMO had an AKI incidence of 26%, and AKI was associated with an adjusted mortality rate that was 3.2 times higher [10] . These findings are similar to those reported by Gadepalli et al. [3] in neonates with a congenital diaphragmatic hernia on ECMO where AKI occurred in 71% of neonates, and those with the highest stage of AKI had a mortality of 73%. Another neonatal population at particularly high risk of developing AKI is those infants with perinatal asphyxia. A recent single-center study found that 36 (38%) of 96 newborns undergoing therapeutic hypothermia had AKI. Even after controlling for important potential confounders, children with AKI on average were ventilated 4 days longer (P < 0.001) and were hospitalized 3.4 days longer (P ¼ 0.023) [11] .
Although in most cases the etiology of AKI is multifactorial, many of the infants in the reported studies were exposed to nephrotoxic medications. Nephrotoxicity represents a potentially avoidable cause of AKI in neonates. In this review, we will summarize what is known about drug-induced nephrotoxicity in neonates, discuss common nephrotoxic medications, and highlight the potential long-term implications of neonatal nephrotoxic AKI.
NEPHROTOXIN-INDUCED ACUTE KIDNEY INJURY
Nephrotoxic-medications are becoming increasingly recognized as a common and potentially modifiable cause of AKI in pediatric patients [12] [13] [14] 15 && ]. In hospitalized children, predisposing factors, such as age, pharmacogenetics, severity of illness, dosage, duration, and concomitant medication, determine and influence the severity of nephrotoxic insult. There have been several recent studies in older children that have investigated the epidemiology impact of AKI induced by nephrotoxic medication. Moffett and Goldstein [14] showed that increasing total nephrotoxic-medication exposure and intensity of exposure, increased the predictive values for the development of AKI in hospitalized noncritically ill children. In this cohort, higher age was noted as a protective factor, and, therefore, infants were at higher risk of developing AKI; in addition, patients with AKI had an increased length of stay in-hospital. They noted that the majority of nephrotoxic medications to which
KEY POINTS
Nephrotoxic medications are commonly prescribed to neonates.
Nephrotoxic-associated AKI can have a profound impact on clinical outcomes in neonates.
Because premature neonates are born with underdeveloped nephrons and low-nephron numbers, the negative impact of nephrotoxins on renal outcomes may be substantial.
Strategies to identify neonates who are exposed to nephrotoxic medications, daily evaluation for signs of AKI, and strategies to prevent toxicity are likely to improve clinical outcomes and resource expenditure. patients were exposed were antimicrobial agents (52%). Aminoglycosides exposure is a frequent cause of AKI. Zappitelli et al. [16] showed that one-third of patients exposed to aminoglycosides developed AKI in a cohort of noncritically ill hospitalized children, which resulted in longer stay and higher total hospital costs. Longer treatment, higher baseline estimated GFR, being on a drug (versus surgical) treatment, and prior aminoglycosides treatment were independent risk factors for AKI in this study.
Under a single-center, and now a multicenter collaborative, Goldstein et al. lead an initiative collaboration to address the issue of pediatric nephrotoxic AKI. The Nephrotoxic Injury Negated by Justin-time Action mission statement is that 'nephrotoxic medications should only be used for as long as they are needed'. Nephrotoxic Injury Negated by Just-in-time Action is a surveillance program whereby all noncritically ill patients are screened for exposure to three or more nephrotoxic medications or three or more days of aminoglycoside exposure. Those who are identified as exposed using these criteria are monitored daily for SCr. Goldstein et al. [15 && ] showed that an electronic health record driven SCr nephrotoxin-AKI surveillance process resulted in a 42% reduction in the number of days with AKI (AKI intensity). Additionally, these investigators also showed that the implementation of daily SCr measurements as part of a hospital-wide quality initiative led to earlier and increased detection of aminoglycoside-associated AKI, compared to every other day SCr measurement, in a cohort of hospitalized patients with cystic fibrosis [17] . Despite the evidence that drug-induced renal dysfunction is a common condition in pediatrics, and that strategies to decrease the damage from nephrotoxic medications can improve outcomes, there is a paucity of information available regarding the epidemiology of this problem in neonates.
NEONATAL NEPHROTOXIC ACUTE KIDNEY INJURY
The neonatal kidney has complex developmental characteristics as nephron development continues until 34 to 36 weeks of gestational age; this could make understanding the pathophysiology, incidence, and outcomes after nephrotoxic medications different in pediatric compared to adult patients. Aspects of the neonatal renal physiology that may increase the likelihood of nephrotoxicity include the fact that most of the medications are predominately excreted through the kidneys, and there is a progressive concentration of filtered and secreted compounds in the tubular lumen [18] . Interestingly, the unique neonatal renal physiology may theoretically protect the kidney from some nephrotoxicity. For example, certain drugs requiring renal tubular transport as an initial toxic pathway (e.g., aminoglycosides and vancomycin) may not achieve their 'full' toxic potential as in an older child, because of immature transport function [19] . Additionally, nephrotoxic medication taken during fetal life or during postnatal nephrogenesis could interfere with nephron generation, contributing to a particular magnitude of damage. Such adjunctive damage could further increase the risk of chronic kidney disease (CKD) in children born prematurely [20] .
The complex nature of neonatal critical illness often requires the use of multiple therapeutic agents, most of which are not labeled for use in infants because clinical trials for safety, dosing, and efficacy of drugs are lacking in this population. Neonates remain an understudied population. In the Food and Drug Administration (FDA) database for pediatric studies submitted between 1997 and 2010, involving 406 pediatric labeling changes, only 6% included new neonatal information [21] . A retrospective review of a national database showed that only 35% of the most commonly prescribed medications in the NICU are FDA approved for infants. In this large cohort, the 10 most commonly reported medications, by exposure, were ampicillin, gentamicin, caffeine citrate, vancomycin, beractant, furosemide, fentanyl, dopamine, midazolam, and calfactant. For extremely low birth weight infants, the 10 most commonly reported medications by exposure were gentamicin, ampicillin, caffeine citrate, vancomycin, furosemide, dopamine, beractant, indomethacin, fentanyl, and albuterol [22 && ].
In a recent investigation of VLBW infants, Rhone et al. [23 && ] highlighted the degree by which neonates are exposed to nephrotoxic medications. In this study, 87% of neonates were exposed to at least one nephrotoxic medication, and on average these neonates were exposed to 14 days of nephrotoxic medications during their NICU stay. The greatest exposure occurred among the smallest, most immature infants. Clearly, the potential to cause harm from medications is present, and strategies to understand ways to mitigate this risk are greatly needed.
NEPHROTOXIC MEDICATIONS

Acyclovir
Acyclovir is used in neonates for the treatment of herpes simplex viral infections and in suspected neonatal sepsis. It is excreted in the urine through filtration and secretion, and is relatively insoluble in urine. Nephrotoxicity can be seen in 17-35% of patients and warrants diligent monitoring throughout treatment [24,25 & ]. Acyclovir nephrotoxicity is classically attributed to tubular obstruction secondary to drug crystallization, but direct tubular toxicity from acyclovir metabolites may also contribute to nephrotoxic potential [26] [27] [28] [29] . Furthermore, acyclovir is transported by shared organic acid transporters with certain b-lactam antibiotics (particularly ceftriaxone), which may increase nephrotoxicity [28, 30] . Nephrotoxicity classically occurs within 48 h of exposure and is more likely in those with impaired renal function, concurrent nephrotoxic exposures, and reduced intravascular volume. To mitigate the nephrotoxic potential, clinicians should aggressively hydrate patients, administer the medication over 1-2 h, adjust dose in those with decreased renal function, and avoid concurrent nephrotoxic medication exposure.
Aminoglycosides
Aminoglycosides still remain as a mainstay for the treatment of neonates with suspected sepsis or documented serious gram-negative infections. The utilization of aminoglycosides is complicated by nephrotoxicity and ototoxicity. Aminoglycosides are freely filtered into the urine and are almost entirely excreted by the kidneys [31 && ]. They accumulate in the proximal tubules by endocytosis and cationic transporters [32] . Approximately 10-15% of filtered aminoglycosides accumulate in the renal cortex in concentrations that may exceed measured systemic concentrations [33] . Intracellular aminoglycosides damage proximal tubular cells by lysosomal accumulation, membrane disruption, disruption of protein production, disruption of mitochondrial adenosine triphosphate production, and oxidative stress [32] . Aminoglycoside toxicity may be also typified by distal tubular dysfunction, polyuria, and antidiuretic hormone resistance.
Aminoglycoside nephrotoxicity is classically nonoliguric in nature and develops later in the treatment course. As a result of their impact on tubular function, aminoglycoside-induced nephrotoxicity may result in a number of electrolyte abnormalities including hypomagnesemia, hypokalemia, hypophosphatemia, and acidosis. Risk factors for nephrotoxicity applicable to neonates include low birth weight, concurrent nephrotoxic medications, prematurity, hypovolemia, sepsis, and hypoxic ischemic encephalopathy [31 && ,34 & ]. At its most extreme, aminoglycoside nephrotoxicity may lead to acute tubular necrosis, oliguria and complete renal failure.
Estimated rates of aminoglycoside-associated nephrotoxicity in neonates vary depending on the definition utilized and the population studied, but is generally lower than in older children and adults. The true incidence of AKI related to aminoglycoside exposure is unclear in neonates, but epidemiological studies will benefit from the utilization of modern definitions. Recent studies have evaluated the impact of aminoglycosides on urinary markers of proximal tubule damage. These studies have shown that aminoglycoside exposure results in the elevation of urinary biomarkers, including those that signify proximal tubular damage, irrespective of rise in SCr [31 && ,35 & ,36]. These data suggest there may be damage resulting from aminoglycoside exposure that is not detected by a rise in SCr, which warrants further study.
In adult studies the hierarchy of nephrotoxicity for aminoglycosides is gentamicin > tobramycin > amikacin > netilmicin. To prevent toxicity, practitioners should diligently monitor drug levels and renal function while on therapy. Because of the differential accumulation of aminoglycosides in the renal cortex, toxicity may occur despite therapeutic drug levels. In an effort to maximize therapeutic benefits and minimize toxicity, extended interval aminoglycoside dosing regimens have been adopted. Extended interval dosing is recommended based on favorable pharmacokinetics, but has yet to be shown to impact rates of nephrotoxicity in neonates [37] .
Amphotericin B
The frequency of neonatal fungal infections has been increasing in neonates and represents a source of significant morbidity and mortality in neonates. Amphotericin B is used as empiric therapy for neonatal fungal infections. Nephrotoxicity represents the most significant side-effect to amphotericin B and results from a combination of vasoconstriction and direct distal tubular toxicity [38] . The direct toxicity and increased tubular membrane permeability accounts for the characteristic electrolyte abnormalities that can be seen with amphotericin B (hypokalemia, hyponatremia, and acidosis hypomagnesemia). The nephrotoxicity associated with amphotericin B in neonates is typically milder than in older children and it is transient in nature, but may be associated with significant morbidity. Liposomal formulations of amphotericin B were developed to reduce the toxicity associated with amphotericin treatment and have been shown to be less nephrotoxic in neonates [39, 40] . The reported incidence of nephrotoxicity utilizing liposomal formulations in neonates ranges from 0 to 20% and it is commonly transient in nature [39] [40] [41] . Risk factors for nephrotoxicity include longer treatment duration, nephrotoxic medications, and severity of illness [42, 43] . The risk of nephrotoxicity can be diminished by avoiding concurrent nephrotoxic medication exposure and potentially by increasing sodium intake (>4 mEq/kg/day) [44] .
Angiotensin converting enzyme inhibitors
The renin-angiotensin system (RAS) is critical to fetal renal development and contributes significantly to renal vascular resistance during the neonatal period through its vasoconstrictive activity. In the kidney, angiotensin acts primarily as a vasoconstrictor at the efferent arteriole (postglomerulus) to maintain glomerular filtration. The implications of blockade of the RAS on the developing fetus are well known and include a spectrum of disorders ranging from papillary atrophy to pulmonary hypoplasia and renal failure [45,46 & ]. These outcomes were worse with exposure to angiotensin receptor blockers and when the exposure occurred in the second and third trimesters. Given the potential deleterious impact on postnatal renal development, it may be appropriate to avoid the use of angiotensin converting enzyme (ACE)-inhibitors in neonates <32 weeks of age, in whom nephrogenesis may not be complete [47] . In a study of captopril treatment in neonates with a congenital heart disease, AKI occurred in 14% of patients and was reversible in all patients [47] . AKI induced by ACE-inhibitors is typically reversible with dose adjustment, increased renal perfusion, or medication discontinuation. As neonatal kidneys are known to be sensitive to RAS blockade, ACE inhibitors should be started at low doses and titrated slowly with diligent monitoring of electrolytes and renal function. To mitigate the risk of AKI with ACE inhibition practitioners should closely monitor intravascular volume (including those on diuretic therapy) and be cautious about concomitant utilization of nonsteroidal antiinflammatory drugs (NSAIDs).
Nonsteroidal anti-inflammatory drugs
Neonates have high levels of circulating prostaglandins, which play an integral role in renal water clearance and afferent arteriolar vasodilatation. Prostaglandins are vasodilators and increase renal blood flow by vasodilation of the afferent arteriole. Prostaglandin levels are high during the neonatal period and act as a key counter-regulatory mechanism to offset the highly vasoconstrictive milieu following birth. Inhibiting prostaglandin synthesis can profoundly decrease neonatal renal blood flow and GFR, causing transient oliguria. Prenatal exposure to NSAID medications can adversely impact renal function with a range of effects, from transient oliguria to oligohydramnios, depending on timing and duration of exposure [48] . NSAID-induced AKI following birth is most frequently related to exposure to ibuprofen or indomethacin and is typically transient in nature; however, occasionally this may be complicated by oliguria, fluid overload, and electrolyte abnormalities. The nephrotoxic side effects are less severe with ibuprofen [49,50 && ,51]. To prevent NSAID-induced AKI, practitioners should ensure adequate intravascular volume, consider using the lowest effective dose, and avoid the use of concomitant nephrotoxic medications.
Vancomycin
The role of vancomycin as a nephrotoxin remains controversial, particularly in the context of monotherapy with appropriate medication levels [52,53 & ]. The exact mechanism of nephrotoxicity remains unclear, but animal models suggest that nephrotoxicity may be related to oxidative effects on the proximal tubule damage [54] . Risk factors for AKI in neonates who receive vancomycin include higher vancomycin troughs, concomitant nephrotoxins or diuretics, positive blood cultures, low birth weight, patent ductus arteriosus, and higher severity of illness [53 & ,55]. Animal models and adult studies have suggested that vancomycin used in conjunction with aminoglycoside or piperacillintazobactem may lead to increased nephrotoxicity [54,56 & ,57] . Given the ability to monitor vancomycin levels and its potential for nephrotoxicity, vancomycin monitoring protocols should be instituted with a daily review of nephrotoxic medications.
PREVENTION OF NEPHROTOXIC-ASSOCIATED ACUTE KIDNEY INJURY
There are currently no approved treatments for established AKI, and therapies are limited to the management of sequelae of AKI. In lieu of successful treatment strategies, there has been renewed interest in the prevention of AKI. Nephrotoxic medication exposure, and by extension nephrotoxin associated AKI, represents an obvious area for intervention in neonates given the high exposure burden. To decrease the incidence of nephrotoxin-associated AKI in neonates, the development of algorithms to screen, monitor, and intervene to reduce harm produced by medication could significantly improve outcomes. These programs would regularly evaluate infants who are at risk for nephrotoxic injury, develop lab monitoring processes for those at risk, and institute intervention strategies to limit the damage caused by nephrotoxic medications. This approach relies on daily evaluations by a multidisciplinary team that includes input from nurses, physicians, residents, and pharmacists.
The most obvious first step in this algorithm is avoiding nephrotoxic medication when feasible, and identifying appropriate alternative medications. When nephrotoxic medications cannot be avoided, a careful inventory of risk factors should be done, including: prior nephrotoxicity, renal function, severity of illness, volume status, nephrotoxic medication burden, and gestational age. The team should focus on mitigating modifiable risk factors when feasible, including reducing nephrotoxic burden, optimizing intravascular volume, reassessing diuretic need, avoiding harmful medication interactions (e.g., NSAIDs and ACE), and using the minimal effective dose (e.g., daily versus multiple-daily aminoglycoside doses).
Once a patient is on nephrotoxic medication(s), diligent monitoring of kidney function becomes paramount. Regular monitoring of kidney function and drug levels (where applicable) should be protocolized to monitor for the development and progression of AKI. Utilization of the electronic medical records represents a potential avenue for monitoring, which has been successful in older pediatric patients. If AKI develops while on a nephrotoxic medication, it is important to also consider other potential causes of AKI.
LONG-TERM EFFECTS OF PREMATURITY AND ACUTE KIDNEY INJURY ON CHRONIC KIDNEY DISEASE
In recent years, long-term follow-up data have begun to identify prematurity as a known risk factor for the development of CKD. A meta-analysis performed by White et al. [58] reported that premature infants (birth weight <2500 g) have nearly twice the odds of having low glomerular filtration rate, microalbuminuria, end-stage renal disease, and hypertension than their term counterparts. Carmody and Charlton [59] recently published a comprehensive overview of the links between prematurity/low birth weight and subsequent CKD in adulthood. Preterm delivery disrupts nephrogenesis, which is normally not completed until approximately 34-36 weeks gestation. A small number of autopsy studies have suggested that nephrogenesis continues for only a short time after birth [60] [61] [62] . The remaining nephrons undergo hypertrophy to compensate for decreased nephron mass, and the resultant 'hyperfiltration' eventually becomes deleterious and leads to glomerulosclerosis with sodium retention, systemic hypertension, proteinuria, and progressive CKD [63] . Thus, these infants are already 'primed' for kidney injury/CKD based on their premature birth.
The full impact of additional AKI events in the NICU on long-term kidney and health outcomes is not yet known. Previously, it was assumed that those who survived an episode of AKI would recover kidney function without long-term sequelae; however, recent data from animals [64] , critically ill children [65, 66] , and adults with AKI suggest that survivors are indeed at risk for development of CKD. A meta-analysis by Coca et al. [67] showed that adults with AKI have a higher risk of developing incident CKD (pooled adjusted hazard ratio 8.8, 95% CI 3.1-25.5), end-stage kidney disease (pooled adjusted HR 3.1, 95% CI 1.9-5.0), and mortality (pooled adjusted HR 2.0, 95% CI 1.3-3.1) compared with patients without AKI.
The role that nephrotoxin-associated AKI plays in the development of CKD in this population is still unknown. Several case reports have documented that CKD occurs in infants who had AKI; however, these studies were small single-center retrospective reports [68] . Unfortunately, follow-up after AKI is not commonly done. In a study by Camody et al. [4 & ], 180 out of 455 neonates (40%) had at least one episode of AKI (75 had multiple episodes). Alarmingly, only 13.5% of infants who were discharged home had a diagnosis of AKI on the hospital discharge summary, and no subjects were referred for follow-up with a pediatric nephrologist. Large multicenter studies designed to determine which factors are associated with long-term CKD are greatly needed to define the most appropriate surveillance protocols, as well as to identify those most at risk. This effort will provide us with the needed in-hospital AKI phenotype to determine the degree to which AKI may impact future development of CKD. In turn, this will guide follow-up recommendations.
CONCLUSION
Neonatal AKI occurs commonly in the NICU and is associated with adverse outcomes. Although the exact rates of nephrotoxin-associated AKI remain unclear, the burden of nephrotoxin exposure in critically ill neonates is high and represents a potentially modifiable risk factor. To prevent or diagnose nephrotoxin a multidisciplinary approach utilizing careful monitoring of nephrotoxic medications (i.e., burden and duration), drug levels, renal function, and risk factors (e.g., birth weight and volume status) is needed. Future work assessing nephrotoxic Drug-induced acute kidney injury in neonates Hanna et al.
medications associated with the development of AKI needs to focus on utilizing standardized definitions, risk stratification, a role for surveillance utilizing the electronic medical record, and the long-term outcomes including the development of CKD in these patients. The epidemiological study showed that VLBW infants are frequently exposed to nephrotoxic medications, receiving approximately 2 weeks of nephrotoxic medications before discharge or 1 for every 6 days of hospitalization. The greatest exposure occurred among the smallest and most immature infants, and on those who experienced AKI. 
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